{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:06:52Z","timestamp":1792206412722,"version":"4.4.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Congenital thrombotic thrombocytopenic purpura (cTTP) arises from an inherited deficiency of ADAMTS13, causing a thrombotic microangiopathy with multisystemic sequelae. Acute cTTP relapse can cause arteriovascular thrombosis, and registry data suggest that later diagnosis and commencement of treatment are associated with increased morbidity. Undiagnosed or \u201cnonovert\u201d cTTP may also be associated with end-organ damage. Treatment is based on ADAMTS13 replacement, previously limited to plasma and factor VIII concentrates and now expanded to recombinant ADAMTS13, which can achieve higher peak and trough levels with smaller volumes. Now that treatment options are improved, we need to focus on prophylaxis and the clinical impact of this lifelong condition. Beyond treatment of acute TTP relapses, symptoms such as headaches, abdominal pain, and lethargy without overt laboratory relapse may reflect subacute TTP and herald later end-organ damage. We need further longitudinal data on how to optimize care. Key questions remain about prophylaxis and how to target optimal control of this condition through the alliance of improved treatment delivery and measures of clinical outcome.<\/jats:p>","DOI":"10.1182\/hematology.2025000759","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:10:22Z","timestamp":1764943822000},"page":"628-635","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Modern management of congenital thrombotic thrombocytopenic purpura (cTTP)"],"prefix":"10.1182","volume":"2025","author":[{"given":"Alice","family":"Taylor","sequence":"first","affiliation":[{"name":"1 Great Ormond Street Hospital for Children, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Scully","sequence":"additional","affiliation":[{"name":"2 University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"4","key":"2025120616352186500_hem2025000759C1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/bjh.19026","article-title":"A British Society for Haematology Guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies","volume":"203","author":"Scully","year":"2023","journal-title":"Br J Haematol"},{"issue":"5","key":"2025120616352186500_hem2025000759C2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","article-title":"Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features","volume":"142","author":"Scully","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"2025120616352186500_hem2025000759C3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2169\/internalmedicine.49.2706","article-title":"Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008","volume":"49","author":"Fujimura","year":"2010","journal-title":"Intern Med"},{"issue":"5","key":"2025120616352186500_hem2025000759C4","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/S2352-3026(16)30018-7","article-title":"Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy","volume":"3","author":"Mariotte","year":"2016","journal-title":"Lancet Haematol"},{"issue":"10","key":"2025120616352186500_hem2025000759C5","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3324\/haematol.2019.216796","article-title":"The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017","volume":"104","author":"van Dorland","year":"2019","journal-title":"Haematologica"},{"issue":"15","key":"2025120616352186500_hem2025000759C6","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2018-11-884700","article-title":"Characterization and treatment of congenital thrombotic thrombocytopenic purpura","volume":"133","author":"Alwan","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2025120616352186500_hem2025000759C7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1067\/mpd.2003.79","article-title":"Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome","volume":"142","author":"Veyradier","year":"2003","journal-title":"J Pediatr"},{"issue":"1","key":"2025120616352186500_hem2025000759C8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/bloodadvances.2023011972","article-title":"Management and follow-up of pregnancy-onset thrombotic thrombocytopenic purpura: the French experience","volume":"8","author":"B\u00e9ranger","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2025120616352186500_hem2025000759C9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2014-02-553131","article-title":"Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes","volume":"124","author":"Scully","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2025120616352186500_hem2025000759C10","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1055\/s-0038-1673686","article-title":"ADAMTS13 gene mutations influence ADAMTS13 conformation and disease age-onset in the French cohort of Upshaw-Schulman syndrome","volume":"118","author":"Joly","year":"2018","journal-title":"Thromb Haemost"},{"issue":"1","key":"2025120616352186500_hem2025000759C11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1365-2141.2002.03809.x","article-title":"Successful treatment of congenital thrombotic thrombocytopenic purpura using the intermediate purity factor VIII concentrate BPL 8Y","volume":"119","author":"Lester","year":"2002","journal-title":"BJ Haem"},{"issue":"1","key":"2025120616352186500_hem2025000759C12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2141.2006.06264.x","article-title":"The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura","volume":"135","author":"Scully","year":"2006","journal-title":"BJ Haem"},{"issue":"10","key":"2025120616352186500_hem2025000759C13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ajh.23527","article-title":"ADAMTS13 content in plasma-derived factor VIII\/von Willebrand factor concentrates","volume":"88","author":"Peyvandi","year":"2013","journal-title":"Am J Hematol"},{"issue":"1","key":"2025120616352186500_hem2025000759C14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/jth.14345","article-title":"Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura","volume":"17","author":"Taylor","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2025120616352186500_hem2025000759C15","first-page":"1215","article-title":"Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura","volume":"111","author":"Allford","year":"2000","journal-title":"Br J Haematol"},{"issue":"10","key":"2025120616352186500_hem2025000759C16","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"19","key":"2025120616352186500_hem2025000759C17","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: first-in- human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2025120616352186500_hem2025000759C18","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2023-188996","article-title":"Recombinant ADAMTS13 for the treatment of acute TTP events in patients with congenital thrombotic thrombocytopenic purpura: results from the phase 3 randomized, controlled, crossover study and the phase 3b continuation study","volume":"142","author":"Scully","year":"2023","journal-title":"Blood"},{"issue":"17","key":"2025120616352186500_hem2025000759C19","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2314793","article-title":"Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura","volume":"390","author":"Scully","year":"2024","journal-title":"N Engl J Med"},{"issue":"20","key":"2025120616352186500_hem2025000759C20","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1182\/blood.2024027516","article-title":"Therapeutic switch from plasma to recombinant ADAMTS13 for patients with congenital TTP from Japanese real-world data","volume":"145","author":"Sakai","year":"2025","journal-title":"Blood"},{"key":"2025120616352186500_hem2025000759C21","unstructured":"US Food and Drug Administration. FDA approves first treatment for patients with rare inherited blood clotting disorder. 2023. Accessed 9November2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-rare-inherited-blood-clotting-disorder."},{"issue":"25","key":"2025120616352186500_hem2025000759C22","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMc2210781","article-title":"Recombinant ADAMTS13 in severe neonatal thrombotic thrombocytopenic purpura","volume":"387","author":"Stubbs","year":"2022","journal-title":"N Engl J Med"},{"issue":"25","key":"2025120616352186500_hem2025000759C23","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1056\/NEJMoa2211113","article-title":"Recombinant ADAMTS13 for hereditary thrombotic thrombocytopenic purpura","volume":"387","author":"Asmis","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"2025120616352186500_hem2025000759C24","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ajh.23706","article-title":"ADAMTS-13 content of plasma-derived factor VIII\/von Willebrand factor concentrates","volume":"89","author":"Kingsland","year":"2014","journal-title":"Am J Hematol"},{"issue":"25","key":"2025120616352186500_hem2025000759C25","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood.2020009801","article-title":"Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura","volume":"137","author":"Tarasco","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2025120616352186500_hem2025000759C26","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/bjh.19723","article-title":"TTP and pregnancy","volume":"205","author":"Gounder","year":"2024","journal-title":"Br J Haematol"},{"issue":"19","key":"2025120616352186500_hem2025000759C27","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood.2019000962","article-title":"How I treat thrombotic thrombocytopenic purpura in pregnancy","volume":"136","author":"Ferrari","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2025120616352186500_hem2025000759C28","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/bloodadvances.2021005760","article-title":"Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura","volume":"6","author":"Borogovac","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025120616352186500_hem2025000759C29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1538-7836.2011.04341.x","article-title":"Natural history of Upshaw- Schulman syndrome based on ADAMTS13 gene analysis in Japan","volume":"9","author":"Fujimura","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2025120616352186500_hem2025000759C30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/jth.13186","article-title":"High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence","volume":"14","author":"von","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"16","key":"2025120616352186500_hem2025000759C31","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1182\/bloodadvances.2024013421","article-title":"Global prevalence of hereditary thrombotic thrombocytopenic purpura determined by genetic analysis","volume":"8","author":"Seidizadeh","year":"2024","journal-title":"Blood Adv"},{"key":"2025120616352186500_hem2025000759C32","unstructured":"Genomics England. Newborn genomes programme. Accessed 23October2024. https:\/\/www.genomicsengland.co.uk\/initiatives\/newborns."}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/628\/2470346\/628taylor.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/628\/2470346\/628taylor.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:35:33Z","timestamp":1765056933000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/628\/556854\/Modern-management-of-congenital-thrombotic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000759","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}